HMG COA Reductase Inhibitor Adverse Reaction
7
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
Physical Activity Levels and Statin Therapy
Exercise-induced Muscle Damage in Statin Users
Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS
Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation
Vitamin D Replacement in Statin-Induced Myopathy
Statin Therapy to Improve Medication Adherence